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DOI 10.1186/s40478-015-0240-0RESEARCH Open AccessCortical tau load is associated with white
matter hyperintensities
Kirsty E. McAleese1*, Michael Firbank1, Madhurima Dey1, Sean J. Colloby1, Lauren Walker1, Mary Johnson1,
Joshua R. Beverley1, John Paul Taylor1, Alan J. Thomas1, John T. O’Brien2 and Johannes Attems1Abstract
Introduction: Cerebral white matter lesions (WML), visualized as white matter hyperintensities (WMH) on
T2-weighted MRI, encompass structural damage and loss of integrity of the cerebral white matter (WM) and
are commonly assumed to be associated with small vessel disease (SVD). However, it has been suggested that
WM damage may also be the result of degenerative axonal loss that is secondary to cortical Alzheimer’s
disease (AD) pathologies i.e., hyperphosphorylated tau (HPτ) and amyloid-beta (Aβ). Here we investigate the
influence of HPτ, Aβ and SVD on WMH severity.
Results: 36 human post-mortem right fixed cerebral hemispheres (mean age 84.4 ± 7.7 years; male: 16, female:
20) containing varying amounts of AD-pathology (AD: 23, controls: 13) underwent T2- weighted MRI with WMH
assessed according to the age related white matter change scale (ARWMC). After dissection, using tissue samples
from the frontal, temporal, parietal and occipital regions from the right hemisphere, we quantitatively assessed
cortical HPτ and Aβ pathology burden by measuring the percentage area covered by AT8 immunoreactivity
(HPτ-IR) and 4G8 immunoreactivity (Aβ-IR), and assessed the severity of WM SVD by calculating the sclerotic
index (SI) of WM arteries/arterioles. HPτ-IR, Aβ-IR, and SI were compared with ARWMC scores. HPτ-IR, Aβ-IR and WM
ARWMC scores were all significantly higher in AD cases compared to controls, while SI values were similar between
groups. ARWMC scores correlated with HPτ-IR, Aβ-IR and SI in various regions, however, linear regression revealed
that only HPτ-IR was a significant independent predictor of ARWMC scores.
Conclusions: Here we have shown that increasing cortical HPτ burden independently predicted the severity of
WMH indicating its potentially important role in the pathogenesis of WM damage. Moreover, our findings
suggest that in AD patients the presence of WMH may indicate cortical AD-associated pathology rather than SVD.
Further studies are warranted to elucidate the pathological processes that lead to WM damage and to clarify if WMH
may serve as a general biomarker for cortical AD-associated pathology.
Keywords: Hyperphosphorylated tau, White matter hyperintensities, White matter lesions, Small vessel disease,
Alzheimer’s disease, Post-mortem MRIIntroduction
Cerebral white matter lesions (WML), as visualized his-
tologically, encompass structural damage and loss of in-
tegrity of the cerebral white matter (WM) due to WM
rarefaction (i.e., demyelination and axonal loss), which is
commonly accompanied by reactive astrocytosis and
edema [21]. WML frequently occur in brains of both de-
mented and non-demented elderly, and are visualized as
white matter hyperintensities (WMH) on pre- and post-* Correspondence: Kirsty.McAleese@ncl.ac.uk
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[22]. Age-associated deep WM changes are distinguishable
as ‘punctate’, i.e., single lesions <10 mm, ‘early confluent’, i.e.,
single lesion <20 mm and/or multiple lesions 10–20 mm
linked by ‘connecting bridges’, or ‘confluent’ changes, i.e.,
confluent area of damage >20 mm in diameter [52]. These
lesions differ from that seen in multiple sclerosis (MS) as
MS WML are typically ovoid in shape, range between 3-
8 mm in diameter and are mainly located in the periven-
tricular WM, posterior fossa and subcortical structures [7].
The Austrian Stroke prevention study indicated that the
prevalence of WMH is between 62–96 % in individuals
aged 45 to 87 years [51]. WMH are associated with a widecle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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and are a frequent co-pathology in Alzheimer’s disease
(AD) [30], which is the most frequent cause of age-
associated dementia [57]. The pathogenesis of WMH is
typically associated with small vessel disease (SVD) of
the WM [20], however; the pathogenic mechanisms
underlying the development of WM damage are not
well understood. Previous longitudinal, neuropatho-
logical and imaging studies suggest a multifactorial aeti-
ology of WML [13, 16, 32, 33, 58, 62] including WM
damage secondary to both SVD- related ischemia and
cortical AD pathology, i.e., depositions of intracellular
hyperphosphorylated tau (HPτ) and extracellular
amyloid-beta (Aβ). SVD alterations are assumed to lead
to disturbed arterial autoregulation, promoting progressive
stenosis that eventual leads to chronic hypoperfusion of the
surrounding WM [26]. The exact pathological mechanisms
of degenerative axonal loss is still unclear, but it is
suggested axonal death occurs in conjunction with AD-
pathology related grey matter atrophy, or via calpain-
mediated degradation of cytoskeletal proteins, activated
by AD pathology-related axonal transport dysfunction
[9, 36]. However, currently neither imaging nor routine
histological techniques allow for differentiation between
ischemic (SVD-related) or neurodegenerative causes
(AD pathology) of WM damage.
Previous studies investigating the relationship be-
tween WM damage with both cortical neurodegenera-
tive pathology and WM SVD used semi-quantitative
methods to evaluate the severity of the respective path-
ology [13, 24, 35]. However, such semi-quantitative
methods provide only a crude estimation of the severity of
pathology [2], while quantitative methods more accurately
reflect the actual amount of pathology present. Therefore,
we quantitatively measured cortical HPτ and Aβ burden,
as well as the degree of vessel wall thickening of WM ar-
teries/arterioles in human post-mortem brains, to deter-
mine the influence of both cortical AD pathology and
SVD on WM integrity that was assessed using post-mortem
T2-weighted MRI.
Materials and methods
Our study cohort consisted of 36 human post-mortem
brains (mean age 84.4 ± 7.7 years; male: 16, female: 20)
with varying amounts of AD-pathology, which were
clinico-pathologically classified as AD: 23, and controls:
13. Mini mental state examination (MMSE) [17] scores
were available for 24 cases (AD: 18; controls: 6). Demo-
graphic and neuropathological characteristics of the
study cohort are shown in Table 1. Brain tissue was ob-
tained at autopsy and stored within the Newcastle Brain
Tissue Resource (NBTR) in accordance with Newcastle
University Ethics Board (The Joint Ethics Committee of
Newcastle and North Tyneside Health Authority, reference:08/H0906/136). After autopsy the right hemisphere, brain-
stem and cerebellum were immersion fixed in 4 % buffered
aqueous formaldehyde solution for 6 weeks.
Post-mortem magnetic resonance imaging
We have previously demonstrated that post-mortem MRI
of fixed hemispheres reliably reflect WM damage as
accurately as an extensive histological assessment at 7 mm
intervals [38]. Briefly, fixed right hemispheres were
removed from formalin solution and were investigated
using a 4.7 T MRI scanner (Bruker Medical, Ettlingen,
Germany): Bruker Biospec 47/60 VAS, (vertical, actively
shielded, the inner-bore width of 60 cm) fitted with a
BGA-38-S gradient system (actively shielded, the inner-
bore width of 38 cm) and a birdcage radio-frequency coil
with a working cross-section of 170 × 240 mm. AT2-
weighted pulse sequence was used: two spin echo images
of effective echo time (TE) = 32/96 ms, repetition time
(TR) = 8200 ms, with slice thickness of 2 mm and planar
resolution of 1.0 × 0.78 mm. Regional WMH were subject-
ively rated, blinded to clinical diagnosis, by two experi-
enced assessors (M.F & J.T.O) according to the age-
related white matter change scale (ARWMC) [60]; score
0, absence of WMH; score 1, ‘punctate’ WMH (<10 mm);
score 2, ‘early confluent’ WMH (<20 mm); score 3, ‘conflu-
ent’ WMH (>20 mm). ARWMC scores were generated for
the frontal and temporal WM and a combined score for
the parietal and occipital WM i.e., parieto-occipital. All
ARWMC scores were combined to calculate mean total
ARWMC score that reflected WMH severity of the entire
hemisphere.
Routine neuropathological assessment
Irrespective of clinical diagnoses, all brains underwent
neuropathological assessment to standardized neuro-
pathological scoring/grading systems, including Thal
phases of Aβ deposition [55], Braak staging of neuro-
fibrillary pathology [6], Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD) scores [40]
and the National Institute on Aging-Alzheimer’s Asso-
ciation (NIA-AA) criteria [41] (Table 1).
Tissue preparation
Six μm paraffin-embedded sections were cut from six
cerebral regions; pre-frontal cortex (Brodmann area
(BA) 10, 9), mid-frontal cortex (BA 8, 9), entorhinal cor-
tex (BA 36, 28), temporal cortex (BA 36), parietal cortex
(BA 40/22), and occipital cortex (BA 17). Tissue sections
were mounted onto 4 % 3-aminopropyltriethoxysilane
(APES)-coated glass slides and histologically stained with
haematoxylin and eosin (H&E). Immunohistochemistry
was performed for HPτ (antibody AT8; dilution 1:4000;
Innogenetics, Ghent, Belgium) and Aβ peptide (clone
4G8; dilution 1:15,000; Signet Labs, Dedham, MA,
Table 1 Characteristics of study cohort
AD Control Statistic (df, p-value)
n 23 13
Age, mean (±SD) 84.26 years (5.67) 84.77 (8.49) t(34) = 1.194, p = 0.241
Gender M:F 10:13 8:7 χ2(1) = 0.444, p = 0.505
PMD, mean (±SD) 49.95, h (22.89) 47.15 (24.43) t(33) = 0.34, p = 0.735
Thal Aβ phase20 Phase 5, n = 23 Phase 0, n = 5 U(34) = 0.000, p = 0.001
Phase 1, n = 3
Phase 2, n = 3
Phase 3, n = 1
Phase 4, n = 1
Braak NFT stage21 NFT stage 6, n = 23 NFT stage 0, n = 2 U(34) = 0.000, p = 0.001
NFT stage 1, n = 1
NFT stage 2, n = 3
NFT stage 3, n = 6
NFT stage 4, n = 1
CERAD22 C, n = 23 Negative, n = 10 -
A, n = 2
B, n = 1
NIA-AA23 High, n = 23 No, n = 5 -
Low, n = 7
Intermediate, n = 1
MMSE17 (±SD) 4.33 (3.9) 28 (2.09) t(22) = 14.07, p = 0.001
Abbreviations: AD Alzheimer’s disease, df degrees of freedom, t Independent samples test, X2 Chi -squared test, F female, M Male, U Mann–Whitney U test, PMD
post mortem delay, Aβ amyloid-beta, NFT neurofibrillary tangle, CERAD Consortium to Establish a Registry for Alzheimer's Disease, NIA-AA National Institute on
Ageing - Alzheimer’s Association criteria for AD neuropathologic change, MMSE mini mental state examination
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formed by microwaving slides in 0.01 mL citrate buffer for
10 min (AT8) or immersed for 1 hour in concentrated
formic acid (4G8). Immunopositivity was detected using
the Menarini X-Cell-Plus HRP Detection Kit (Menarini
Diagnostics, Winnersh-Wokingham, UK) with 3,3 diamino-
bezidine (DAB) as a chromagen and haematoxylin as a
counter stain. Sections were subsequently dehydrated
through a series of alcohols, cleared and mounted using
DPX (CellPath, Powys, UK).
Quantification of protein aggregates - image analysis
Image analysis was performed blinded to neuropatho-
logical diagnosis. On tissue sections immunostained for
AT8 and 4G8, 24 cortical sample areas were identified for
analysis. Sample location included sulci, midsection and
gyri in order to yield an accurate mean measure of cortical
pathological burden as protein aggregates have been
shown to be highest in the sulcus and lowest in the gyral
tip [18, 39] (Fig. 1). For image analysis, a Nikon 90i micro-
scope coupled to a PC with NIS-Elements AR3.2 software
(Nikon, Surrey, UK) was used. At each sample location
3x3 single images were captured at 200x magnification
and combined to create one large image representing anarea of 1.7 mm2. If necessary, large images were subjected
to manual setting of regions of interest to exclude WM
and meningeal structures. Pixels in the binary layer were
used to measure immunoreactivity (IR). Red Green Blue
(RGB) thresholds for binary layer pixels were standardized
separately for AT8 and 4G8 and set at a level that was
reached by immunopositive pathological structures only
(i.e., neurofibrillary tangles (NFT), neuropil threads, and
Aβ plaques). RGB intensity values are measured on a scale
between 0 and 255 (see NIS elements version 3.0, user
guide, 2008, Nikon, Surrey, UK) and were set as follows;
AT8: R25-170, G27-156, B11-126; 4G8: R50-180, G20-
168, B8-139. In addition to RGB thresholds, we also set a
size restriction threshold for the assessment of 4G8, which
excluded the measurement of immunoreactive signals
with an area below 100 μm2; this was necessary to ensure
that physiological APP that is stained with 4G8 antibody
was not included, and did not contribute to false positive
values. The area covered by IR was stated as the percent-
age of the total measured area and the respective values
are expressed as HPτ-IR (AT8) and Aβ-IR (4G8). Mean
regional values for frontal, temporal (including the ento-
rhinal cortex), parietal and occipital cortical HPτ-IR and
Aβ-IR were calculated. Regional HPτ-IR and Aβ-IR values
Fig. 1 Cartoon illustrating the 24 locations used for image analysis encompassing sulci, midsection, and gyri from prefrontal (a), mid frontal (b),
entorhinal (c), temporal (d), parietal (e) and occipital (f) cortices. White dots indicate the sampling location; numbers refer to Brodman areas,
which are marked with coloured patterns (modified from [46])
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values, respectively, which reflected cortical pathological
burden of the entire hemisphere.
Sclerotic index
The sclerotic index (SI) is a quantitative measure of ar-
terial and arteriolar vessel wall thickness and has been
shown to be an accurate indicator for the severity of
SVD [31, 61]. The standard formulae SI = 1 - (internal
diameter/external diameter) was used; the SI of normal
arteries and arterioles ranges from 0.2 to 0.3, while an SI
of 0.3 to 0.5 indicates mild to moderate SVD and SI
values >0.5 are seen in severe SVD [31]. On H&E
stained tissue sections, adjacent to the ones used to de-
termine HPτ-IR (AT8) and Aβ-IR (4G8; Fig. 1), the SI of
WM vessels was examined, blinded to neuropathological
diagnosis, using a Nikon 90i microscope at 200x magni-
fication. Eight randomly selected cerebral WM arteries
and/or arterioles >50 μm diameters were identified per
section and a single image captured using a DsFi1 camera.
SI was calculated using the software program VasCalc as
previously described [61]. SI values from the eight individ-
ual vessels from temporal, parietal and occipital WM were
used to calculate mean values for each WM region. Eight
individual SI values from both the pre- and mid-frontal
WM were combined and used to calculate a mean valuefor the frontal WM. All regional SI scores were taken to
calculate a mean total SI value to reflect the severity of
SVD in the entire hemispherical WM.
Statistical analysis
The Statistical Package for Social Sciences software (SPSS
ver. 21) was used for statistical evaluation. Variables were
tested for normality using the Shapiro-Wilk test and visual
inspection of variable histograms. Subsequently, group ef-
fects were assessed using either non-parametric (Mann–
Whitney U) or parametric procedures (independent sam-
ples test). Where appropriate, partial Spearman’s (ρ') and
Pearson’s (r') correlation coefficients (one tailed) were
used to assess associations between ARWMC scores and
HPτ-IR, Aβ-IR and SI (controlling for the effects of age at
death). Exploratory forward stepwise linear regression
analyses were also conducted to investigate predictors of
ARWMC scores.
Results
Differences between total cortical HPτ/Aβ burden, total
WM SVD severity and severity of WMH between AD and
controls
As expected, total cortical HPτ-IR was significantly higher
in cases clinico-pathologically classified as AD compared
to controls (p = 0.001, Fig. 2a), as was total cortical Aβ-
Fig. 2 (See legend on next page.)
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Fig. 2 Total cortical percentage area covered by HPτ-IR (AT8 antibody for hyperphosphorylated tau burden) and 4G8 immunoreactivity (Aβ-IR; for
amyloid-β burden), total white matter sclerotic index (WM SI; measure of small vessel disease severity), and total age related white matter change
scale (ARWMC; measure for white matter hyperintensities) scores in Alzheimer’s disease (AD) i.e., cognitively impaired, and controls. a, total HPτ-IR
is significantly higher in AD as compared to controls. (ai), hyperphosphorylated tau in the form of neurofibrillary tangles and neuropil threads is
immunopositive for AT8 antibody (neurofibrillary tangle - arrow, neuropil thread - arrow head) and (aii) the area covered by AT8 immunopositivity
(shaded in red) was measured to calculate HPτ-IR. b, total Aβ-IR was significantly higher in AD as compared to controls. (bi), Aβ plaques/depositions
are immunopositive for 4G8 antibody and (bii) the area covered by 4G8 immunopositivity (shaded in red; arrow indicates physiological APP that is not
included in the analysis) was measured to calculate Aβ-IR. c, No differences were seen in the severity of small vessel disease as measured by sclerotic
index (SI) between controls and AD. (ci), small white matter artery, histologically stained with H&E. (cii) example for calculating the SI: using VasCalc
software [61] the internal (Dint) and external (Dext) diameters were measured three times to yield a SI value (for details see main text). d, Total
age related white matter change (ARWMC) scores [60] were significantly higher in AD compared to controls. Examples of post mortem T2 MRI:
(di), no WMH (ARWMC score 0) and (dii) confluent white matter hyper intensity in the parieto-occipital region (arrow head; ARWMC score 3).
MR images were captured in sagittal plane. *,p < 0.05; ***,p < 0.001; scale bar, 20 μm, valid for ai and bi, 50 μm for ci
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fer significantly between AD and controls (p = 0.241,
Fig. 2c), while total ARWMC scores were also signifi-
cantly higher in AD relative to controls (p = 0.031,
Fig. 2d).Correlations between cortical HPτ/Aβ burden and WM
SVD severity with severity of WMH
To investigate the associations between cortical HPτ/Aβ
burden and WM SVD severity with WMH scores, we
performed partial Spearman’s (ρ') and Pearson’s (r') cor-
relation analyses, controlling for age at death, across
various topographic regions and the entire brain (Fig. 3).
Analysis revealed that cortical HPτ-IR values correlated
with ARWMC scores in all regions; frontal, ρ' = 0.312,
p = 0.032; temporal, ρ' = 0.472, p = 0.002; parietal, ρ' =
0.450, p = 0.003 and occipital ρ' = 0.325, p = 0.028, as well
as the entire hemisphere (ρ' = 0.408, p = 0.007). Correla-
tions were also observed between ARWMC scores and
cortical Aβ-IR values in all regions and for the entire
hemisphere; frontal, ρ' = 0.326, p = 0.026; temporal, ρ' =
0.455, p = 0.003; parietal, ρ' = 0.354, p = 0.017; occipital,
ρ' = 0.400, p = 0.008; total, ρ' = 0.492, p = 0.001. However,
correlations between ARWMC scores and WM SI were
observed only in the occipital lobe (r' = 0.303, p = 0.043)
and not the frontal (r' = 0.273, p = 0.056), temporal (r' =
0.284, p = 0.061) or parietal (r' = 0.210, p = 0.113) regions. A
correlation was revealed between total values of ARWMC
scores and WM SI (r' = 0.311, p = 0.035), however this is
likely due to the correlation in the occipital region.Neuropathological predictors of WMH
To investigate whether the burden of cortical neurode-
generative pathology (i.e., HPτ and Aβ) and severity of
SVD in the WM independently predicted WMH score,
stepwise linear regression analyses were performed for
each region with ARWMC scores as the dependent vari-
ables and cortical HPτ-IR, cortical Aβ-IR, WM SI scores
and age at death as independent variables.In the temporal region, only HPτ-IR was a significant
predictor (model R2 = 0.270, F(2) = 5.359, p < 0.001; β =
0.532, p = 0.003) while the remaining independent vari-
ables were not significant predictors (cortical Aβ-IR: β =
0.081, p = 0.087; WM SI: β = 0.306, p = 0.358; age at
death: β = 0.194, p = 0.245). With respect to the frontal
and parietal regions, both cortical HPτ-IR (frontal:
model R2 = 0.208, F(2) = 4.32, p < 0.001; β = 0.340, p =
0.022; parietal: model R2 = 0.280, F(2) = 6.410, p < 0.001;
β = 0.417, p = 0.009) and age at death (frontal: β = 0.398,
p = 0.018; parietal: β = 0.384, p = 0.015) were significant
predictors but not cortical Aβ-IR (frontal: β = 0.059, p =
0.725; parietal: β = 0.068, p = 0.068) nor WM SI (frontal:
β = 0.204, p = 0.248; parietal: β = 0.129, p = 0.149). In the
occipital regions, only age at death was a significant pre-
dictor (model R2 = 0.135, F(1) = 4.819, p < 0.001; β =
0.367, p = 0.036) but not HPτ-IR (β = 0.297, p = 0.081),
Aβ-IR (β = 0.266, p = 0.114) or WM SI (β = 0.147, p =
0.252). With respect to the entire hemisphere, total cor-
tical HPτ-IR (model R2 = 0.331, F(2) = 8.162, p < 0.001; β
= 0.514, p = 0.001) and age at death (β = 0.386, p = 0.012)
were significant predictors but not total cortical Aβ-IR
(β = 0.074, p = 0.075) or total WM SI (β = 0.179, p =
0.235).
Associations between HPτ/Aβ burden and WM SVD with
WMH in cases with minimal cortical neurodegenerative
pathology
To investigate whether the association between WM
SVD and WMH in cases with minimal cortical HP-τ
burden differs from the one observed in the entire study
cohort (of which 63.9 % were AD cases with moderate
to high cortical HP-τ burden), we restricted the ana-
lysis to control cases classified as Braak NFT stage 0-II
(n = 6), which exhibit no or only minimal cortical HP-
τ pathology. We investigated associations between
total cortical HPτ/Aβ burden, total WM SVD severity
and age at death with total WMH scores. No correl-
ation was seen between age at death and total
ARMWC score (ρ = 0.235; p = 0.327), therefore, Spearman’s
Fig. 3 (See legend on next page.)
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Fig. 3 Partial Spearman’s (ρ') (HPτ-IR and Aβ-IR) and Pearson’s (r') (WM SI) correlation coefficients controlling for the effect of age at death. Scatter
graphs show correlations between cortical percentage area covered by HPτ-IR (AT8 antibody for hyperphosphorylated tau burden), Aβ-IR (4G8;
for amyloid-β depositions/plaques) and total white matter sclerotic index (WM SI; measure of small vessel disease severity) with age related white
matter change score (ARWMC; measure for white matter hyperintensities) in the frontal (a-c), temporal (d-f), parietal (g-i) and occipital (j-l) regions, as
well as total values representing the entire hemisphere (m-o). Analysis revealed that in all regions, and the entire hemisphere, significant correlations
were observed between ARWMC scores and cortical HPτ-IR and Aβ-IR values, respectively. A significant relationship between ARWMC
scores and WM SI were observed only in the occipital lobe. Of note, a correlation was observed between total SI and total ARWMC
scores but this is likely due to the correlation in the occipital region. Only significant p values (and associated correlation coefficients (ρ’,
r’)) are shown; for all correlation please see main text
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employed. Here, the correlation between total WM SI
and total ARWMC score appears much stronger (ρ =
0.883; p = 0.01; Fig. 4a) than the one observed for the
entire study cohort (r' = 0.311, p = 0.035; Fig. 3o), which
is driven only by the correlation in the occipital region.
Additionally, no significant correlations were seen be-
tween both total cortical HPτ-IR (ρ = −0.433; p = 0.196
Fig. 4b) and total cortical Aβ-IR (ρ = 0.27; p = 0.303;
Fig. 4c) with total ARWMC score.
Discussion
Here, we demonstrate that in frontal, temporal and par-
ietal regions, as well as in the entire hemisphere, cortical
HPτ burden predicted the severity of WMH independ-
ent of both cortical Aβ burden and WM SVD severity.
However, in cases virtually lacking cortical HPτ path-
ology we found a strong correlation between the sever-
ities of SVD and WMH.
WMH is a descriptive term for diffuse, low-density
changes of the cerebral WM as seen on T2-weighted
MRI images. Despite the assumption that WMH are the
result of SVD, the underlying pathogenesis is unclear
and appears to be associated with a heterogeneousFig. 4 Correlations between total white matter sclerotic index (a) (WM SI; m
percentage area covered by HPτ-IR (b) (AT8 antibody for hyperphosphoryla
depositions/plaques) with age related white matter change score (ARWMC
hyperphosphorylated tau pathology (classified as Braak NFT stage 0-II [6]). O
was seen between total cortical HPτ-IR and Aβ-IR with total ARWMC scores
are shownmixture of vascular and degenerative processes as deter-
mined by previous studies [24, 32, 33, 62], and our data
that demonstrated increasing WMH severity with in-
creasing cortical HPτ and Aβ pathology, SVD severity,
and age. As expected, age at death was associated with
increasing WMH severity as age is one of the strongest
risk factors related to the development of WMH [8], as
well as being associated with increasing AD-related path-
ology [11] and dementia. In agreement with previous
studies [4, 47, 50] we found significantly more severe
WMH in AD i.e., cognitively impaired cases compared to
controls, however, no respective differences were seen
with regard to the severity of SVD suggesting that SVD
may not be the main underlying cause for WMH in AD.
Moreover, only cortical HPτ pathology independently pre-
dicted the severity of WMH when calculations were per-
formed for frontal, temporal and parietal regions, as well
as the entire hemisphere. These findings further point to-
wards an important role of increasing amounts of cortical
HPτ pathology in the pathogenesis of WMH. It is import-
ant to note that the accumulation of AD-pathology fre-
quently occurs in normal aged individuals without
compromising cognitive function [5, 23, 25, 56], therefore,
the impact of HPτ pathology on WM damage may not beeasure of small vessel disease severity) as well as total cortical
ted tau burden) and 4G8 (c) immunoreactivity (Aβ-IR; for amyloid-β
; measure for white matter hyperintensities) in cases with minimal
nly total WM SI (a) correlated with total ARWMC score; no correlation
. Only significant p values (and associated correlation coefficients (ρ))
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dementia.
This association between increasing HPτ pathology
and increasing WMH severity corroborates previous
neuropathological-imaging studies that reported an asso-
ciation between increasing Braak NFT stage and increas-
ing WMH severity [13, 24]. Furthermore, tau protein
has been implicated in the clinical conversion from MCI
to AD as shown in a recent study by Tosto and col-
leagues, who demonstrated that in MCI participants
with high cerebral spinal fluid level of total-tau, higher
parietal WMH volume predicted conversion to AD [59].
In addition, our data implicating HPτ pathology as a
predictor for WMH severity in the temporal and parietal
WM confirms neuropathological studies reporting WM
damage in AD to predominately affect the temporal [12]
and parietal [35] WM. However, these studies were
based on semi-quantitative assessment that provides
only a crude estimation of pathological burden [6, 55],
while our study implemented quantitative assessment
that better reflects the actual amount of pathology and
seems better suited to identify associations between dif-
ferent types of pathological lesions.
Despite our data indicating WM damage in cases with
cognitive impairment is associated with HPτ pathology,
the underlying mechanism of how HPτ causes axonal
loss remains unclear. Two possible pathomechanisms
have been proposed; firstly, neuronal death is associated
with the accumulation and deposition of HPτ pathology
[19], which may lead to the disintegration of associated
axons. Secondly, in neurodegenerative diseases with pro-
tein aggregation and deposition, including AD, major
synaptic and axonal loss can precede the loss of the
neuronal soma [10, 49]. This type of axonal loss, which
is independent of neuronal death, is thought to be the
result of dysfunction and/or blockage of fast anterograde
axonal transport [9, 42]. With respect to the develop-
ment of HPτ pathology, the hyperphosphorylation of the
microtubule-associated tau protein leads to the
destabilization of the principal cytoskeletal component
microtubules that are critical for fast anterograde trans-
port in axons [36]. Impairment of axonal transport is
thought to activate the cysteine protease calpain, result-
ing in the retrograde degradation of axonal cytoskeletal
proteins and subsequent loss of the axon fibre [9, 36].
Both of these suggested mechanisms might explain our
finding of increasing cortical HPτ burden independently
predicting the severity of WMH.
In cases with minimal HPτ pathology, categorized as
Braak NFT stage 0-II, we found a strong correlation be-
tween increasing WM SVD and WMH severities confirm-
ing previous pathologic and imaging studies demonstrating
an association between SVD and WM damage [45, 52]. Of
note, the small sample size of six cases was a limitation andrepeat studies are warranted using a larger cohort. This
finding is also in agreement with a number of recent contri-
butions that point to the independence of WMH from clas-
sical AD biomarkers [27, 29, 43]. On the other hand, in the
entire study cohort, cases with higher HPτ pathology bur-
den and cognitive impairment exhibited significantly higher
ARWMC scores compared to controls, while no significant
differences were seen in the severity of WM SVD. More-
over, the severity of WM SVD failed to predict WMH
score. Taken together, our findings suggest that in general,
both cortical HPτ pathology and WM SVD may lead to the
development of WMH; however, in neurodegenerative dis-
eases such as AD, WMH are primarily associated with
cortical HPτ pathology, while WM SVD may be an add-
itional contributing factor. On the other hand, in cases vir-
tually lacking cortical HPτ pathology, WM SVD seems to
play an important role in the development of WMH. SVD
is complex and heterogeneous and our assessment was lim-
ited to the measurement of the vessel wall thickness i.e.,
measure of fibrosis only, therefore, future studies may war-
rant assessment of other SVD-related pathologies, e.g.,
blood brain barrier breakdown and perivascular space en-
largement. Additionally, we did not assess other possible
causes of ischemic damage such as cerebral amyloid antip-
athy, orthostatic hypotension, and myocardial infarction.
Our study incorporated the use of post-mortem T2
weighted MR imaging for the assessment of WMH.
There is currently limited data directly comparing hu-
man in vivo and post-mortem MRI imaging of WMH
and the effects of fixation on MR characteristics. One
such study by Macchi and colleagues compared MS le-
sions in vivo and post-mortem MRI scan from a single
MS patient and determined that the MRI signal and
contrast from the post-mortem scan was satisfactory
compared to the in vivo scan [37]. Furthermore, an in-
vestigation into the effects of fixation on quantitative
MRI of human brain slices revealed there were no sig-
nificant changes detected in WMH and normal appear-
ing WM after fixation [53]. Further studies are
warranted to elucidate any significant alteration of MR
characteristics as a result of the fixation process. Never-
theless, MRI and histopathology comparative studies have
previously shown that post-mortem MRI of formalin fixed
tissue is a reliable method to obtain data on both the se-
verity and distribution of WM damage [14, 15, 38, 52].
Neuroimaging is emerging as an important biomarker
in the diagnosis of pre-symptomatic AD and multiple
studies have indicated regional specific WM damage in
AD patients compared to normal ageing. Reduced frac-
tional anisotropy (indicative of reduced tissue integrity)
on diffusion tensor imaging (DTI) is frequently seen in
the WM of the posterior regions, i.e., parietal, temporal
and occipital lobes [1, 3, 4], as well as the major fiber
bundles, i.e., inferior and superior longitudinal fasciculi
McAleese et al. Acta Neuropathologica Communications  (2015) 3:60 Page 10 of 11[34], the parahippocampus [44] and corpus callosum [4].
Previous neuroimaging studies have demonstrated asso-
ciations between increasing changes in WM and cortical
atrophy in AD [1, 3], which could possibly be explained
by WM damage resulting from axonal loss caused by
HPτ-related neuronal death.
Conclusions
Clinical diagnosis and decision making in dementia is
partly based on neuroimaging e.g., medial temporal lobe
atrophy is associated with AD [28], while WMH are usu-
ally regarded as an indicator of vascular cognitive impair-
ment/dementia [48]. However, given that AD is the most
common cause of age-associated dementia [57], our find-
ings strongly suggest that WMH in cognitively impaired
individuals rather indicate cortical AD associated neuro-
degenerative pathology than SVD/CVD. Hence, current
interpretation of WM neuroimaging may result in inad-
equate management of patients and be detrimental for the
stratification of patient cohorts in clinical trials. Further
studies are warranted to better determine the underlying
pathological processes that may lead to WMH.
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